Abstract Body

Background:

Robust induction of CD8+ T cells play important role in control of HIV-1 viremia. Here, we describe design and implementation of approaches to recruit cytotoxic T-cell responses for achieving HIV-1 clearance. We have exploited a combination of two critical immune components, first is the HIV virus neutralization property of the Broadly Neutralizing Antibodies (bNAbs) and second – the killer potential of cytotoxic T cells as DNA launched therapeutic intervention against HIV-1.

Methods:

We designed DNA launched broadly neutralizing killers (bNKs) which are single chain molecules, these engage CD3+ T cells from one arm and HIV-1 infected target cells using the other arm. Multiple bNKs for targeting various sites of vulnerabilities present on HIV-1 Env protein like CD4bs, V1/V2 loop, etc. have been developed. We evaluated the expression profiles of these DNA launched bNKs and characterized for functionality in terms of binding, neutralization and killing by recruitment of effector cells first in vitro and then in vivo. ELISA and flow cytometry was employed for binding studies, followed by pseudo-neutralization assays to test neutralizing potential of these therapeutics against global virus panel. A novel cell based Xcelligence assay was designed to use impedance as a readout for killing activity of bNKs in the presence of effector T cells and their potency were defined.

Results:

PGDM1400-bNK and 3BNC117-bNK were designed and optimized for expression both in vitro and in vivo. These were found to be functional and bound CD3 expressing T cells along with capacity to neutralize HIV-1 Tier2/3 viruses with high potency and specificity. These were found to be extremely potent killers against HIV-1 infected target cells with picogram IC50 for killing. Further, IM administration in mice using electroporation was performed and the serum expressing the bNKs exhibited cytolysis and killing of HIV-1 infected cells in novel cell based Xcelligence assay.

Conclusions:

Our data highlights the design and characterization of novel DNA launched bNKs which are potent double-edged therapeutics capable of broadly neutralizing difficult to neutralize Tier2/3 viruses and engaging effector T cells to their targets and mediate killing of HIV-1 infected cells with high potency and specificity. Further designs are being currently explored to use these molecules as combination therapies to engage various other effector cells of the immune system and target arresting HIV-1 virus escape using our robust HIV therapy.